ArticleClinical rheumatology2026
MICA protein as a plasma biomarker for dermatomyositis with malignancy: a proteome-wide Mendelian randomization and ELISA study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionDermatomyositis (DM) is an autoimmune disease marked by distinctive cutaneous manifestations and systemic involvement, including an increased risk of malignancy. Proteome-wide Mendelian randomization (MR) revealed plasma major histocompatibility complex class I-related chain A (MICA) as a potential malignancy biomarker in DM, followed by validation with the enzyme-linked immunosorbent assay (ELISA) method.
methodsWe performed a proteome-wide MR analysis using protein quantitative trait loci data from the deCODE-2021 database and genome-wide association study data of DM from the Finnish Finngen R11 cohort. The causal relationship between plasma protein levels and DM was evaluated by a variety of MR techniques, such as weighted median, Wald ratio, MR-Egger, and inverse-variance weighted (IVW). Colocalization analysis was conducted to determine whether MICA shares genetic susceptibility loci with DM. To validate our findings, serum MICA levels were measured using ELISA in 47 patients with DM/CADM (clinically amyopathic dermatomyositis), eight cancer patients without DM/CADM, and 14 healthy controls.
resultsMR analysis revealed that elevated plasma MICA levels are significantly associated with an increased risk of DM (OR = 1.56, 95% CI = 1.33-1.82, P = 4.90e
conclusionThese results highlight MICA as a novel biomarker for malignancy risk in DM, providing potential clinical utility for identifying patients at high risk. Key Points • This study demonstrates a significant causal association between elevated plasma MICA protein levels and an increased risk of developing dermatomyositis using proteome-wide Mendelian randomization. • ELISA-based validation in a clinical cohort confirms that serum MICA levels were significantly elevated in patients with DM/CADM, especially those with malignancy, supporting its role as a malignancy biomarker.
Indexed as
Identifiers
41239078What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.